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Summary In a previous study using RNA in situ hybridisation (RISH), we found a significant correlation
between high mobility group protein I/Y, [HMG-I(Y)] mRNA expression and tumour stage and grade in
prostate cancer patients, suggesting that HMG-I(Y) might be a potential prognostic marker in prostate cancer.
However, our clinical follow-up was limited because cryopreserved material was used. Assessing the potential
prognostic value of this molecule is of importance because the clinical course of prostate cancer patients
remains unpredictable. Here we describe our results on paraffin-embedded archival material from a group of
102 patients undergoing radical prostatectomy. These were evaluated for the presence of HMG-I(Y) using
RISH, and a follow-up of 12-92 months (average 53 months) was available. In 2 of 14 prostate cancers in
which the predominant histological pattern was of Gleason grade 1-2, a high HMG-I(Y) expression was
observed, whereas in 19 of 23 Gleason grade 3, and 34 of 35 Gleason grade 4-5 tumours, high HMG-I(Y)
mRNA levels were detected (chi-square= 38.78, P<0.0001). Moreover, of tumours that expressed high HMG-
I(Y) levels, 25% were organ confined (TI -2), in contrast to 74.5% of the invading tumours (T3, chi-
square= 15.8, P<0.001). Furthermore, 87% of recurrent tumours showed high HMG-I(Y) expression.
However, a multivariate regression analysis including Gleason grade, clinical tumour stage, HMG-I(Y)
expression and prostate-specific antigen (PSA) levels showed Gleason grade as the most accurate predictor of
progression. High HMG-I(Y) levels measured by RISH were indicative of a worse prognosis, albeit that
additional value over the more subjective grading methods was not evident.
Keywords: RNA in situ hybridisation; high mobility group protein; archival material; radical prostatectomy;
multivariate analysis; prognostic marker
Prostate cancer is the most common malignancy among
males (Boring et al., 1994). Preventive screening programmes
reveal more organ-confined lesions, leading to an increase in
the number of radical prostatectomies. However, this may
not have a significant impact on overall survival as these
tumours show a variable clinical course that cannot be
predicted with the current available markers. Thus, patients
with the same disease status may or may not progress
(Johansson et al., 1989; Adolfsson et al., 1990; Bostwick et
al., 1993) after radical prostatectomy. As cancer cells undergo
aberrant patterns of differentiation, it is likely that their
phenotype, including cellular components responsible for
differentiation, might be modified. Several biological markers
have been studied in prostate cancer, but their prognostic
value is unknown. Some markers have been found to be
associated with the onset of prostatic cancer, i.e. increased S-
phase and elevated transforming growth factor (TGF)-/3,
(Nagle et al., 1991). Other investigators have shown a
correlation between the high expression of Ki-67, proliferat-
ing cell nuclear antigen (PCNA), MIB-1, and recurrent or
metastatic disease (Bostwick et al., 1992; Skalova et al.,
1994). We and others have shown that loss of E-cadherin, a
molecule involved in maintaining tissue integrity, is
associated with progression in prostate cancer (Umbas et
al., 1992, 1994). Furthermore, decreased E-cadherin immu-
noreactivity correlated not only with tumour grade and
clinical stage but also with poor prognosis in patients with
prostate cancer (Umbas et al., 1994), identifying E-cadherin
as a potential useful prognostic marker.
We have recently identified high mobility group protein I/
Y [HMG-I(Y)], as a putative progression marker for
prostate cancer (Bussemakers et al., 1991). HMG-I(Y)
belongs to a family of chromosomal non-histone proteins
that is composed primarily of the isoform proteins HMG-I
and HMG-Y (Johnson et al., 1988, 1989) and the closely
related HMGI-C (Manfioletti et al., 1991). Members of the
HMG-I(Y) family are distinguished from other groups of
HMG proteins by their ability to specifically bind to the
minor groove of A: T-rich DNA sequences (Elton et al.,
1986; Solomon et al., 1986), presumably similar to anti-
tumour and antiviral drugs (netropsin, distamicin) and the
dye Hoechst 33258 (Disney et al., 1989; Wegner et al., 1990).
In addition to its involvement in chromosome condensation
(Yang-yen et al., 1988; Giancotti et al., 1989), recent reports
suggested another possible role of HMG-I(Y) as a
transcription regulatory factor (Fashena et al., 1992;
Skalnik et al., 1993). Moreover, the cell cycle-dependent
p34CdC2 like kinases phosphorylate the DNA-binding domains
of HMG-I(Y) both in vitro and in vivo (Meijer et al., 1991),
which may serve as an important regulatory mechanism for
DNA-binding modulation (Disney et al., 1989). A striking
correlation between elevated levels of HMG-I(Y) and both
neoplastic cell transformation (Giancotti et al., 1987;
Johnson et al., 1988) and metastases (Bussemakers et al.,
1991; Ram et al., 1993) has been found. In prostate cancer,
we have shown significant correlation between HMG-I(Y)
mRNA expression, Gleason grade and clinical stage
(Tamimi et al., 1993). This finding prompted us to further
analyse this molecule for its value as progression marker.
We report here on the retrospective study of HMG-I(Y)
mRNA expression in 102 radical prostatectomy specimens.
As in our previous study (Tamimi et al., 1993), image
analysis techniques were applied to quantitate mRNA
expression as detected by RISH. The results were compared
with Gleason grade, clinical stage and, more importantly, to
the recurrence of the disease.
Materials and methods
Specimens from 102 consecutive radical prostatectomies
performed in our institutions from 1985 to 1992 were
Correspondence: JA Schalken, Urological Research Laboratory,
University Hospital Nijmegen, PO Box 9101 6500HB, Nijmegen,
The Netherlands
Received 15 August 1995; revised 16 February 1996; accepted 4
March 1996HMG-I(Y) as marker for prostate cancer
Y Tamimi et al
574
included in this study. Samples were fixed in formalin and
embedded in paraffin. A complete pathological examination
was subsequently performed for each patient including pelvic
lymph nodes. All the slides were reviewed by one of us
(HGP) and, for each patient, a representative block was
chosen for further analysis. In order to have accurate
measurement of mRNA levels, paraffin-embedded tissue
from the MAT-LyLu tumour, a metastatic subline of the
Dunning rat prostatic cancer model system, was taken as an
external reference. This allowed a good estimation of the
technique's effectiveness. HMG-I(Y) is well conserved
between species (85% homology between human and rat)
and moderately expressed in MAT-LyLu.
Preparation ofparaffin sections
Serial sections from each paraffin-embedded block (each
block corresponds to one patient) were cut at 4 ,um
thickness, mounted on slides covered with a 2% tissue
adhesive glue solution and placed on a heating plate
overnight at 50°C. The sections were deparaffinised,
rehydrated in phosphate-buffered saline (PBS)
(1 x PBS = 137 mM sodium chloride, 2.7 mM potassium
chloride, 8.1 mM disodium hydrogen phosphate, 1.5 mM
potassium hydrogen phosphate pH 7), washed for 5 min in
0.1 M glycine/PBS and incubated in 0.3% Triton X-100/PBS
for 10 min. After a short rinse in PBS, sections were treated
with proteinase K (10 jug ml-') in 20 mM Tris-HCl, pH 7.5,
5 mM EDTA for 15 min, post fixed in 4% paraformalde-
hyde/PBS for 5 min, rinsed in PBS and acetylated in freshly
prepared 0.25% acetic anhydride/0.1 M triethanolamine,
pH 8, for 10 min (Hayashi et al., 1978). The slides were
then finally dehydrated in gradually increasing concentra-
tions of ethanol before hybridisation.
In situ hybridisation
Preparation of [35S]UTP RNA probe, hybridisation, washing
conditions and the preparation of microautographs were
performed as described previously (Tamimi et al., 1993).
Preservation of RNA
In order to judge RNA preservation, samples were hybridised
with sense and antisense 28S rRNA probes. The antisense
rRNA probe signal had to exceed 1O x background to be
considered for inclusion in the study. Samples with poorly or
no preserved RNA (13%, 13 of 102) were rejected from the
analysis. Moreover, samples presenting an experimental
failure in the external reference (9%, 9 of 102), or lacking
follow up (3%, 3 of 102) were not studied.
Quantitation by image analysis
The system consisted of a video camera (MXR, HCS,
Eindhoven) mounted on a routine light microscope, and a
personal computer (Compaq Deskpro 386s, Compaq,
Houston, TX, USA) equipped with a framegrabber board
(VFG Visionplus-AT, Imaging Technology, Bedford, MA,
USA). The output image was presented on a video monitor
(PVM 1442QM, Sony, Tokyo). Software was written in TIM-
image analysis language (TEA, Dordrecht). For each tumour
area corresponding to highest Gleason grade, five images
were randomly recorded at 40 x magnification. A Laplace
filter was applied for grain identification. The mean number
of grains per image was calculated for each slide and the
following score for in situ HMG-I(Y) mRNA estimation
could be derived:
Score A = mRNAHMG-I(Y)(+) mRNAHMG-I(Y)(-)
mRNAref.(+) - mRNAref.(-)
This calculates the expression of HMG-I(Y) (+) mRNA
normalised for an external reference.
Statistical analysis
For a comparison of the means corresponding to the four
groups (Benign, Gleason grade: 1-2, 3 and 4-5), the analysis
of variance (F-test) was performed on the A score (see
previous paragraph). The recurrence rate ofpatients that have
higher or lower HMG-I(Y) mRNA expression compared with
a determined threshold was evaluated according to Kaplan-
Meier (Kaplan et al., 1958), and the differences between
groups were performed using the log-rank test.
Threshold determination
Although the choice of a cut-off value is arbitrary, it should
not disequilibrate the groups in such a way that statistical
methods are not applicable any more. The mean value +(1
or 2) x s.d. is the commonly used option in this particular
case. We have chosen the mean value of Gleason grade 1-2
plus 1.5 s.d. =0.65 as a cut-off value for this study.
Results
In order to evaluate the potential prognostic value of HMG-
I(Y) expression in prostate cancer by RISH, we used archival
specimens obtained after radical prostatectomy. Tissues were
fixed in formalin, embedded in paraffin and stored until use.
Expression ofHMG-I(Y) determined by RISH
By rRNA hybridisation (rRNA+), 75% of the samples
showed appropriate RNA preservation and were investigated
for the presence of HMG-I(Y) mRNA by RISH. Table I
summarises the HMG-I(Y) expression as the mean A
values+s.d. for the non-malignant tissue, and prostate tissue
of Gleason grade 1-2, 3 and 4-5 respectively. In the non-
malignant specimens the signals did not exceed background
levels (Figure 1, a-d). We concluded that under these
conditions HMG-I(Y) expression was below the detection
limit of this technique.
Gleason grade 1-2 tumours
Fourteen cases of Gleason grade 1 -2 (well-differentiated
tumours) (Gleason et al., 1977) showed clear expression of
HMG-I(Y), specifically on cancer cells within the glands. The
mean expression level was 0.42+0.16.
Gleason grade 3 tumours
Expression of HMG-I(Y) was detected in areas of the 23
moderately differentiated tumours (Figure 1, e-h). Two
samples gave a lower signal similar to well-differentiated
tumours. The mean HMG-I(Y) expression was 0.95+0.38.
Gleason grade 4-5
Thirty-five samples ofpoorly differentiated tumours showed a
strong signal specific to tumour cells. A higher 'grain density'
was obtained in this category of tumours when compared
Table I HMG-I(Y) expression in prostate cancer determined by
RISH on paraffin-embedded tissue from patients who underwent
radical prostatectomy
Mean ofscore
Differentiation Number of cases A ±s.d.
Benign 6 0.03+ 0.04
Gg (1-2) 14 0.42+0.16
Gg (3) 23 0.95+0.38
Gg (4-5) 35 1.34+0.52
HMG-I(Y) mRNA levels expressed as normalised A score (see
Materials and methods) in non-malignant (B), Gleason grade (Gg) 1-
2, Gleason grade 3, and Gleason grade (4-5) tumours.with Gleason grade 1 -2 and Gleason grade 3 tumours
(Figure 1, i-l).
Table II summarises our statistical analysis. Statistically
significant differences in HMG-I(Y) expression levels between
all groups were found (see t and P-values in Table II). The
analysis indicated that HMG-I(Y) expression increased with
Gleason grade (see Figure 2). Considering that increased
expression of HMG-I(Y) might be associated with aggres-
siveness and invasiveness of tumours, we evaluated whether
HMG-I(Y) expression (over the fixed threshold of 0.65)
correlated with clinical stage. High HMG-I(Y) expression
(A>0.65) was associated with high-stage disease, i.e. 25% in
T1+T2 vs 91% in T3 and T4 (chi-square= 15.8, P=0.001,
see Table III).
PSA levels and HMG-I(Y) expression correlation
In order to assess whether the disease had already spread
outside the prostate after radical prostatectomy in those cases
of high Gleason grade, we compared patient levels of PSA
with the expression levels of HMG-I(Y). PSA was measured
periodically (once per 6 months) during the follow-up of the
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patients. Among 102 patients analysed, PSA levels rise above
0.5 ng ml-' in only 11 patients. Most of these high-level PSA
patients are high-stage (ten patients pT3, one patient pT2)
and high-grade (three patients Gleason grade 4, four patients
Gleason grade 3, four patients Gleason grade 2) however,
only five patients showed high HMG-I(Y) expression
(A>0.65). A further regression analysis demonstrated that
PSA level as measured after radical prostatectomy has no
additional value in this study.
Progression analysis
Follow up of patients ranged from 12 to 96 months. Forty-
three per cent (31 of 72) showed evidence of progression
clinically or biochemically, i.e. PSA>0.5 ng ml-' (five
cases). Most of these patients (90%, 28 of 31) showed
high HMG-I(Y) expression in their tumour specimens
(A>0.65), with the majority falling into clinical stage 3
disease (77.5%, 24 of 31).
Kaplan-Meier analysis showed a significant correlation
between HMG-I(Y) expression and progression (Figure 3
log-rank test: chi-square =5.0175, P=0.025).
Figure 1 Representative examples of RISH original magnification ( x40) on a non-malignant tissue (a, b, c, d) malignant specimens of Gleason grade 3 (e, f, g, h) and 4-5 (i, j, k, 1). Paraffin-embedded sections were hybridised with antisense rRNA (a, e, i), sense rRNA (b, f, j) (to assess RNA preservation). The hybridisation was performed with antisense HMG-I(Y) (c, g, k), and the sense HMG-I(Y) (d, h, 1) to evaluate HMG-I(Y) expression.
I
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Discussion
Increased HMG-I(Y) mRNA levels are often found in
rapidly proliferating or undifferentiated cells and in various
malignant tissues including prostate cancer (Lund et al., 1983;
Elton et al., 1986; Johnson et al., 1988; Bussemakers et al.,
1991). Furthermore, induction of differentiation results in the
down-regulation of HMG-I(Y) mRNA expression, suggesting
that HMG-I(Y) expression is associated with cellular
differentiation (Vartianen et al., 1988). In a previous study
we showed that in specimens of non-malignant prostate
tissue, HMG-I(Y) expression was absent, whereas HMG-I(Y)
expression was clearly detectable in prostate cancer cells
(Tamimi et al., 1993). Moreover, a statistically significant
correlation between the level of HMG-I(Y) expression and
Gleason grade and stage was found (Tamimi et al., 1993).
The present data on archival specimens confirm our previous
findings (Figure 2) and corroborate the hypothesis that
HMG-I(Y) expression is related to differentiation. Indeed, in
well-differentiated tumours 2 of 14 cases (14%) showed low
HMG-I(Y) expression, whereas 83% (19 of 23) ofmoderately
differentiated and 97% (34 of 35) of poorly differentiated
tumours showed high HMG-I(Y) expression (chi-
square=38.78, P<0.0001). This strong correlation between
tumour grade and HMG-I(Y) expression, determined by
RISH, suggests that this might be used as an additional
prognostic indicator for prostate cancer. However, a multi-
variate regression analysis, which included Gleason grade,
tumour stage, HMG-I(Y) expression and PSA levels showed
Gleason grade as the most accurate predictor of progression
(chi-square=21.35, P<0.0001). In this study, high HMG-
I(Y) levels as measured by RISH were indicative of a worse
prognosis, although additional value over the more subjective
grading methods was not evident.
We found that HMG-I(Y), as measured with image
analysis, was highly expressed in 14 of 27 cases of tumours
(51%) that were organ confined (TI -2) in contrast to 41 of
45 tumour cases (91%) invading through the prostate capsule
(T3-4). Thus, there seems to be a trend towards higher
HMG-I(Y) levels in higher stage tumours, which might be a
Table II Statistical analysis ofdata obtained on paraffin tissue from
a patient who underwent radical prostatectomy
Group Mean values ofA +s.d. t-value P-value
Gg 1-2 0.42 ±0.16 4.79 (<0.0001)
Gg 3 0.95 ±0.38
Gg 1-2 0.42 ±0.16 6.03 (<0.0001)
Gg 4-5 1.34 ±0.52
Gg 3 0.95 ±0.38 3.07 (=0.0030)
Gg 4-5 1.34 ±0.52
t-test was performed to compare (two by two) the groups for their
HMG-I(Y) expression. Gg, Gleason grade.
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reflection of the higher numbers of biologically aggressive
cells in the latter tumours. Furthermore, 28 of 31 patients
(90%) that showed recurrence of disease showed high HMG-
I(Y) expression (A>0.65). This is in agreement with previous
studies on mouse teratocarcinoma cells (Vartianen et al.,
1988) and mouse neoplastic cells induced by different
procedures (Giancotti et al., 1989). In the present study we
show that patients with low HMG-I(Y) expression are at low
risk of recurrence as only 3 of 17 (17.6%) relapsed. In
contrast, patients with high HMG-I(Y) expression had a high
frequency of recurrence in 28 of 55 cases (51%). However,
HMG-I(Y) expression was not indicative of progression in all
cases: in three patients with low HMG-I(Y) expression
(A<0.65), and low-stage disease (TI one case, T2 two
cases) relapses were observed. The reverse was also observed
in two patients: low HMG-I(Y) was measured despite high
Gleason grade and stage. Nevertheless, HMG-I(Y) expression
might be predictive for the malignant potential of prostate
cancer cells.
The mechanism by which the HMG-I(Y) gene is regulated
in prostate tissue remains to be elucidated. The proteins are
present in abundance (105-106 molecules per cell), which
indicates that they could be involved in the regulation of
many genes, some of which might be involved in cell growth.
Recently, Friedmann et al. (1993) localised the HMG-I(Y)
gene to the short arm of chromosome 6 in a region where
rearrangements, translocations and other abnormalities have
been found in numbers of human cancers.
HMG-I(Y) has been implicated in a number of functions:
the subunits of NF-KB (p50 and p65), members of the
oncogene rel family, can only activate transcription from
their binding site PRDII when HMG-I(Y) is also bound
(Thanos et al., 1992), similarly the E-selectin gene, encoding
for endothelial cell adhesion proteins, can be activated only
via interleukin (IL)-13 and tumour necrosis factor (TNF)-cx
induction of NF-KB through HMG-I(Y) binding (Lewis et
al., 1994). HMG-I(Y) is involved in rescuing scaffold-
associated regions (SARs) and A:T rich sequences from
histone HI-mediated repression, which fold the chromatin
fibre into higher order structures (Zhao et al., 1993); finally
HMG-I(Y) plays a role in the suppression of IL-4
transcription in T lymphocytes (Chuvpilo et al., 1993), as
well as in the stimulation of a specific isoform of the
activating transcription factor 2 (ATF-2195) binding to
interferon ,B (IFN-fl) (Du et al., 1994). In view of the
multifunctionality of HMG-I(Y) in mammalian cells, it is not
Table m Relation between HMG-I(Y) expression levels and stages
Ti T2 T3 T4
A<0.65 0 13 4 0
A>0.65 1 13 40 1
Correlation between stage and HMG-I(Y) expression over and
below a threshold of0.65 (normalised score A).
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Figure 2 Correlation of HMG-I(Y) expression with Gleason
grade (Gg) in prostate cancer.
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Figure 3 Kaplan-Meier progression free rate related to HMG-
I(Y) expression. Log-rank test: chi-square=5.017, P= 0.025.
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surprising that high HMG-I(Y) expression is important in
cancer progression. The results presented here indicate that
measurement of HMG-I(Y) levels in prostate cancer may be
useful as a prognostic marker. However, the technical
difficulties of RISH should be taken into account for routine
use. The development of less cumbersome techniques for
HMG-I(Y) detection, i.e. immunohistology, is necessary
before this can be implemented.
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